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OUT OF POCKET EXPENSES FOR BREAST CANCER SURVIVORS: 
DIFFERENCES BY TIME SINCE DIAGNOSIS IN A RURAL POPULATION
Pisu M, Azuero A, McNees P, Burkhardt J, Meneses K
University of Alabama at Birmingham, Birmingham , AL, USA
OBJECTIVES: The out-of-pocket (OOP) expenses for care related to breast cancer 
can be burdensome for survivors. We know little about the kind and amount of OOP 
for survivors’ care, health maintenance and management of side effects. The objective 
is to report on expenses in 150 participants in the Rural Breast Cancer Survivor 
Intervention (RBCS), a clinical trial evaluating a psychoeducational quality of life 
intervention. METHODS: Breast cancer survivors recruited for the trial were 1–3 
years post diagnosis, at least 21 years old and residing in rural Florida. OOP data 
collected at baseline included expenditures for Medical Care (hospital, ER, and 
doctors’ bills, medical supplies, drugs, travel to treatment, physical therapy), Counsel-
ing and Health Maintenance (family or individual support, alternative treatments, 
nutritional counseling, exercise or gym/health club memberships, genetic testing/coun-
seling), Side Effect Management (wigs, prostheses), and Home Maintenance (house 
cleaning/cooking, additional maintenance or child care). We report mean monthly 
costs for the period from diagnosis to baseline. RESULTS: Of 150 mostly white 
women, 91.3% were insured, 30.0% had incomes > $50,000, and 60.7% were >24 
months post diagnosis. A total of 94.7% reported OOP spending (mean $119.6, 
median $53.6). Medical Care costs and Home Maintenance costs were highest, $129.3 
and $87.6, respectively, for women 25–36 months post diagnosis. Medical Care costs 
were lowest for women >49 months post-diagnosis, $33.7, and Home Maintenance 
costs were lowest, $15, for women 10–24 months post-diagnosis. Counseling and 
Health Maintenance and Side Effect Management costs were highest ($43 and $14, 
respectively) for women 10–36 months post-diagnosis and lowest ($20 and $8) for 
women 37–48 months. CONCLUSIONS: Rural breast cancer survivors continue to 
have OOP costs related to their disease years after diagnosis. Understanding how and 
how much they spend is important information to be considered in cost-effectiveness 
analyses of interventions to improve their quality of life.
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COST OF ILLNESS FOR PATIENTS WITH METASTATIC  
COLORECTAL CANCER
Song X1, Zhao Z2, Barber B2, Gregory C3, Cao Z1, Gao S2
1Thomson Reuters, Cambridge , MA, USA, 2Amgen, Inc, Thousand Oaks, CA, USA, 
3Thomson Reuters, Washington, DC, USA
OBJECTIVES: To estimate the cost of illness and assess the primary cost drivers of 
treating patients with newly diagnosed metastatic colorectal cancer (mCRC) after the 
introduction of biologic therapies. METHODS: Patients newly diagnosed with mCRC 
between 2004 and 2008 were identiﬁed using a large national claims database of a 
US commercially insured population. Patients were followed from initial mCRC 
diagnosis to death, disenrollment, or 7/31/2009, whichever occurred ﬁrst. mCRC costs 
were estimated by the cost difference between mCRC patients and their matched 
non-cancer cohorts. mCRC patients and controls were 1:1 matched on age, gender, 
geographic region, calendar year of diagnosis, and Deyo-Charlson Comorbidity Index. 
Both total and component costs (inpatient, emergency room, outpatient, or pharmacy/
biologics) were analyzed. The multivariate, survival-based M1 method was used to 
estimate costs in order to handle a variable length of follow-up and data censoring 
issues. RESULTS: A total of 6,746 mCRC patients met all eligibility criteria for the 
study. They were matched to patients without cancer, resulting in a 98.9% match rate 
and a ﬁnal sample of 6,675 mCRC patients were included in this study. Mean (stan-
dard deviation) age was 64.1 (13.1) and 62.6 (14.1) for cases and controls, respec-
tively, and 55.5% were males in both cohorts. Compared with matched patients 
without cancer, total monthly costs were $14,585 higher for mCRC patients, which 
was mainly driven by higher cost of inpatient ($7,546) and outpatient ($4,197) care, 
accounting for over 80% of the total health care costs attributable to mCRC. CON-
CLUSIONS: The economic burden of mCRC is substantial. Inpatient and outpatient 
care remain key cost drivers in the medical management of mCRC.
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BURDEN OF INPATIENT CASES OF ACUTE EXACERBATIONS OF COPD 
WITH LUNG CANCER IN THE UNITED STATES IN 2006
Perera P1, Skrepnek G2
1College of Pharmacy, University of Arizona, Tucson, AZ, USA, 2University of Arizona 
College of Pharmacy Center for Health Outcomes and PharmacoEconomic Research, 
Tucson, AZ, USA
OBJECTIVES: To determine: 1) hospitalization charges of acute exacerbations of 
chronic obstructive pulmonary disease (AECOPD) with lung cancer; and 2) the clini-
cal, socio-demographic, and hospital characteristics associated with inpatient charges. 
METHODS: A retrospective study of the Agency for Healthcare Research and Quality 
(AHRQ) Healthcare Cost and Utilization Project (HCUP) Nationwide Inpatient 
Sample for 2006. An AECOPD was identiﬁed via ICD-9-CM codes in the ﬁrst three 
diagnosis positions: 1) 491.2x identifying AECOPD; 2) 490.x-492.x and 494.x-496 
identifying COPD with either pneumonia (480.x-486); or a procedure code for 
mechanical ventilation (93.90, 96.70–96.72) in any position. Lung cancer in AECOPD 
was identiﬁed by the ICD-9-CM code 162.x. Discharge records were included if 
patients ≥40 years. Regression analyses were conducted using generalized linear model 
with gamma family with charges as the primary outcome. Signiﬁcance was set a priori 
at the 0.05 level. RESULTS: A total of 42521 hospital discharges with mean(±SD) 
hospitalization charge of $33436(±43647) and length of stay of 7.0(±6.8) days. In-
hospital mortality was 10.6%. The majority was ≥65 years (73.6%), male 
(55.2%), had ≥4 comorbidities (62%), with Medicare as the primary payer (75.0%). 
Among cases that reported race, 84.6% were white. Age <65 year, black race (com-
pared to white), hospitals with larger bed size, urban hospitals (compared to rural), 
in-hospital mortality, greater number of comorbidities, and presence of speciﬁc cor-
morbidities such as congestive heart failure, arrhythmias, pulmonary circulation dis-
orders, cerebrovascular disease, and weight loss were signiﬁcantly associated (p≤0.01) 
with increased hospitalization charges. The Midwest and South (compared to North-
east) regions, Medicaid (compared to Medicare) and comorbidities such as depression 
and ischemic heart disease were signiﬁcantly (p≤0.05) associated with decreased 
charges. CONCLUSIONS: The inpatient burden of AECOPD with lung cancer is 
substantial with a number of socio-demographic, hospital and clinical characteristics, 
particularly other comorbidities prevalent in COPD, associated with hospitalization 
charges.
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MORTALITY COSTS FROM GENITAL CANCERS IN MEN—UNITED 
STATES, 2004
Li C, Ekwueme DU, Rim SH, Tangka FK
Center for Disease Control and Prevention, Atlanta, GA, USA
OBJECTIVES: To estimate mortality costs measured as years of potential life lost 
(YPLL) and productivity loss in 2004 due to deaths from all cancers and from genital 
cancers speciﬁcally among men in the US. METHODS: To estimate YPLL, we used 
2004 national mortality data and life tables by multiplying the number of deaths and 
average remaining life years for speciﬁc age groups. To estimate lifetime productivity 
loss, we applied the human capital approach by multiplying the number of deaths by 
the expected value of decedents’ future earnings estimated using the American Time 
Use Survey, accounting for both the market value and the imputed value of housekeep-
ing services. We calculated results for age and racial/ethnic groups and for four catego-
ries of male genital cancer (prostate, testicular, penile, and other). RESULTS: In 2004, 
deaths from male genital cancers accounted for 309,921 YPLL, 6.8% of the estimated 
4.5 million YPLL attributable to deaths from all cancers among US men. Prostate 
cancer accounted for 94.2% of the YPLL, and testicular cancer accounted for the 
highest average number of YPLL per death (37.9). Non-Hispanic whites accounted 
for 75.9% of the YPLL from male genital cancer deaths, and non-Hispanic blacks had 
the highest YPLL rate (297.0/100,000 men). Overall, genital cancers had the largest 
relative contribution to YPLL among men aged ≥50 years compared to other age 
groups. In 2004, the estimated lifetime productivity loss due to deaths from male 
genital cancers was $5.4 billion, 5.7% of the estimated $97.9 billion loss due to deaths 
from all cancers among US men. CONCLUSIONS: Male genital cancers impose a 
considerable health and economic burden in terms of premature deaths and productiv-
ity loss in the United States.
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RETROSPECTIVE COST AND OUTCOME ANALYSIS OF BREAST 
CANCER PATIENTS TREATED IN A BRAZILIAN OUTPATIENT CANCER 
CENTER (OCC)
Teich N1, Souza CPR1, Teich V1, Cintra M1, Musacchio JG2, Vieira FM1
1MedInsight, Rio de Janeiro, Rio de Janeiro, Brazil, 2COI—Clinicas Oncológicas Integradas, 
Rio de Janeiro, Rio de Janeiro, Brazil
OBJECTIVES: To determine the cost and outcome related to breast cancer patients 
treated in a Brazilian OCC in Rio de Janeiro, Brazil. METHODS: This is a retrospec-
tive study of women with breast cancer treated at a private practice OCC in Rio de 
Janeiro, Brazil. All the patients were covered by Amil, a Brazilian HMO. Direct costs 
(DC) of 199 patients diagnosed since 2002 and followed to the end of 2009 were 
analyzed and correlated to clinical stage. We used Kaplan-Meier method to analyse 
patients’ outcome. RESULTS: Forty-eight percent of women were diagnosed in stage 
I, 34% patients in stage II, and only 2.5% were diagnosed in stage IV, similar numbers 
to those seen in developed countries. The average DC of their medical care per patient 
was 21,658.94 USD for stage I compared to 48,295.29 USD for stage II, and were 
63,662.06 USD for stage III and 63,697.33 USD for stage IV. We also observed that 
DC per patient-year increased according to clinical stage. In the ﬁrst year, average cost 
was 15,183.85 USD for stage I, while it was 44,160.74 USD for stage IV. Those DC 
decreased along the years in all stages. For example, in the seventh year of follow-up, 
the average DC was only US$ 467.27 for stage I (2005 purchasing power parity index 
1 USD = 1.4 BRL). The 5-year overall survival and progression free survival were 
100% and 100% for stage I, 92.2% and 91.9% for stage II, 87.5% and 82.1% for 
stage III, and 60% and 60% for stage IV, respectively. CONCLUSIONS: Breast cancer 
accounts for a signiﬁcant part of the health insurance budget. Later stage at diagnosis 
is associated with higher DC per patient-year of treatment, and lower probability of 
5-year survival.
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HEALTH CARE COST OF BREAST CANCER: A CLAIMS DATA ANALYSIS
Fu AZ1, Chen L2, Christiansen NP3, Sullivan SD4
1Cleveland Clinic, Cleveland, OH, USA, 2Sanoﬁ-Aventis, Bridgewater, NJ, USA, 
3Medical University of South Carolina, Charleston, SC, USA, 4University of Washington, 
Pharmaceutical Outcomes Research and Policy Program, Seattle, WA, USA
OBJECTIVES: There is a paucity of updated literature on the total direct costs of 
breast cancer (BC) from a US managed care perspective. This study was conducted to 
analyze the economic burden of BC with a focus on direct health care cost in the US. 
METHODS: This was a retrospective matched cohort study using a large claims 
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database from a US national commercially-insured population (January 1, 2003-Sep-
tember 30, 2008). Women aged ≥18 were selected with ≥2 BC diagnoses on different 
dates within 90 days. The date of the ﬁrst BC diagnosis was the index date for case 
cohort. The control cohort (without BC diagnosis) was selected with a 3:1 ratio by 
matching to the cases based on index date (same year and month), age (5-year range), 
region, employer, and health insurance type. Both cohorts were required to have 
continuous enrollment for at least 6-months prior to and 12-months after the index 
date. Generalized linear model (GLM) was applied to evaluate the 1-year post-index 
cost difference between cases and controls with adjustment of demographics, comor-
bid conditions, and pre-index total health care cost. RESULTS: Based on the selection 
criteria, 140,228 patients were included with mean (SD) age of 52.1 (7.5) years. The 
total 1-year health care costs for cases and controls were $61,167 and $6,296, respec-
tively (p < 0.001). GLM predicted that the adjusted incremental health care cost was 
$42,401 (p < 0.001) per BC patient per year, which included 12%, 86%, and 2% for 
inpatient, outpatient, and prescription use. CONCLUSIONS: This study demonstrated 
that breast cancer is an expensive disease condition, which consumes on average 
$40,000 more per patient within the ﬁrst year of diagnosis for the US health care 
system. Most of the direct health care cost is spent in outpatient care settings.
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INDIRECT COST ASSOCIATED WITH BREAST CANCER TO  
US EMPLOYERS
Fu AZ1, Chen L2, Christiansen NP3, Sullivan SD4
1Cleveland Clinic, Cleveland, OH, USA, 2Sanoﬁ-Aventis, Bridgewater, NJ, USA, 3Medical 
University of South Carolina, Charleston, SC, USA, 4University of Washington, Seattle, WA, 
USA
OBJECTIVES: Few data exist on the impact of breast cancer (BC) on absenteeism and 
short-term disability (STD) to employers. This study was undertaken to estimate BC 
related indirect cost impacts within the US population. METHODS: This was a ret-
rospective matched cohort study using a large health care claims database from a US 
national commercially-insured population (2003–2007). Women aged ≥18 were 
selected with ≥2 BC diagnoses on different dates within 90 days. The date of the ﬁrst 
BC diagnosis was the index date for case cohort. The control cohort (without BC 
diagnosis) was selected with 1:1 matching to cases based on index date (same year 
and month), age (5 year range), region, employer, and health insurance type. Continu-
ous enrollment for at least 6-months prior to and 12-months after the index date was 
required for both cohorts. Indirect cost was measured by days of absenteeism and 
STD, multiplied by age-matched average wage rates from Bureau of Labor Statistics. 
Two-part model was used to assess the 1-year post-index indirect cost difference 
between cases and controls with the adjustment of demographics, comorbid condi-
tions, and pre-index total health care cost. RESULTS: Based on the inclusion criteria, 
856 and 2668 patients were selected for absenteeism and STD outcomes, respectively. 
Costs of absenteeism were $4972 and $2937, and costs of STD were $7199 and $653 
for cases and controls, respectively, within the post-index year (both p < 0.001). Two-
part models predicted that the adjusted incremental costs for absenteeism and STD 
were $1911 and $6157 (p < 0.001) per BC patient per year. CONCLUSIONS: This 
study demonstrated that breast cancer is associated with approximately $8000 more 
in indirect cost per patient to the employer within the ﬁrst year of diagnosis.
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INITIAL COSTS OF TREATMENT AMONG STAGE IV PROSTATE 
CANCER (PCA) CHEMOTHERAPY PATIENTS IN SEER-MEDICARE
Onukwugha E, Mullins CD1, Seal B2, Hussain A3
1University of Maryland School of Pharmacy, Baltimore, MD, USA, 2Sanoﬁ-Aventis 
Pharmaceuticals, Bridgewater, NJ, USA, 3University of Maryland School of Medicine, 
Baltimore, MD, USA
OBJECTIVES: Little is known about how resource utilization in the initial treatment 
period among advanced stage PCa patients differs between those receiving versus those 
not receiving chemotherapy, even for docetaxel, the earliest approved agent for meta-
static disease. METHODS: We analyzed patients aged 66 or older from the linked 
Surveillance, Epidemiology, and End Results & Medicare (SEER-Medicare) database. 
Patients were diagnosed with PCa between 2000 and 2005 and were followed until 
censoring. We restricted the cohort to patients with incident Stage IV disease (AJCC-
TNM classiﬁcation) and at least 24 months of post-diagnosis follow-up data. Initial 
costs (Medicare payments) were deﬁned as costs incurred from 2 months before 
diagnosis to 12 months post-diagnosis and patients were stratiﬁed according to whether 
they received chemotherapy, and subsequently, whether they received docetaxel. 
RESULTS: Application of the inclusion criteria resulted in 4,088 Stage IV PCa patients, 
of which 23% (N = 933) reported chemotherapy. Among chemotherapy users, 63% 
(N = 592) received docetaxel-containing regimens. Initial costs totaled $78.3M while 
PCa-speciﬁc initial costs totaled $49.9M. For the full sample (F), chemotherapy 
subsample (C), and no chemotherapy subsample (NC), the proportions of total costs 
attributed to PCa-speciﬁc inpatient costs (IC), non-PCa-speciﬁc IC, PCa-speciﬁc out-
patient costs (OC), non-PCa-speciﬁc OC, and other costs were distributed as follows: 
1) PCa-speciﬁc IC: F = 26.5% [$20.7M]; C = 23.4% [$4.7M]; NC = 27.5% [$16.0M] 
2) non-PCa-speciﬁc IC: F = 12.3% [$9.7M]; C = 10.3% [$2.1M]; NC = 13.1% [$7.6M] 
3) PCa-speciﬁc OC: F = 35.9% [$28.1M]; C = 42.1% [$8.5M]; NC = 33.8% [$19.6M] 
4) non-PCa-speciﬁc OC: F = 20.8% [$16.3M]; C = 22.5% [$4.5M]; NC = 20.1% 
[$11.7M] and 5) Other costs: F = 4.5% [$3.5M]; C = 1.7% [$0.3]; NC = 5.5% 
[$3.2M]. The proportion of PCa-speciﬁc outpatient costs was higher in the docetaxel 
subsample compared to the chemotherapy subsample. CONCLUSIONS: Among 
patients diagnosed with advanced disease, PCa-speciﬁc inpatient and outpatient costs 
accounted for two-thirds of Medicare payments, with PCa-speciﬁc outpatient costs 
gaining larger shares in the chemotherapy and docetaxel subsamples.
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ASSESSMENT OF HEALTH CARE UTILIZATION AND COST AMONG 
METASTATIC MELANOMA PATIENTS IN A US MANAGED CARE 
POPULATION
Ray S, Ganguli A, Luo Y, Xu Y
Abbott Laboratories, Abbott Park, IL, USA
OBJECTIVES: Metastatic Melanoma (MM) is associated with serious clinical and 
humanistic burden. This study calculated the cost and medical resource utilization 
attributable to MM in a large geographically diverse commercially insured US popula-
tion. METHODS: The MEDSTAT MarketScan® database (1/1/2000–12/31/2008) 
identiﬁed patients aged ≥18 years with ≥2 melanoma claims (ICD-9-CM 172.xx, 
V10.82), or ≥1 melanoma claim and ≥1 chemotherapies. After excluding patients with 
other malignant tumors and those with <1 month post-index or <6 months of pre-
index, 2 mutually exclusive cohorts were formed. Patients with diagnosis of metastasis 
or related chemotherapies were categorized as MM, and the remaining as non-MM. 
Index-date was the ﬁrst date of diagnosis of melanoma or MM respectively. Mean 
estimates of per-patient-per-month (PPPM) resource utilization and cost (in 2008 
dollars) within each group (pre vs. post) were statistically compared. Attributed cost 
of metastasis was the difference in mean differences (post-pre) between the groups. 
RESULTS: The study identiﬁed 407 MM and 13,796 non-MM patients (mean age 
48.8 and 47.8 years, respectively). For the MM patients, PPPM utilization increased 
3 to 12 times from the pre-metastatic period (inpatient: 0.007 to 0.090, emergency 
room: 0.010 to 0.044, ofﬁce: 0.724 to 2.592, all with p < 0.0001, and hospital out-
patient: 0.226 to 1.029, p = 0.0442), while the PPPM total cost increased 7 times 
($803.2 to $5,439.9, p < 0.0001). For the non-MM patients, utilization increased 
marginally following melanoma diagnosis (inpatient: 0.005 to 0.008, emergency 
room: 0.012 to 0.016, ofﬁce: 0.696 to 1.214, and hospital outpatient: 0.136 to 0.291, 
all p < 0.0001). The total cost for non-MM patients doubled following diagnosis of 
melanoma ($432.3 to $955.2, p < 0.0001). Upon metastasis, the disease attributed 
cost increased 9 times ($523 to $4638). CONCLUSIONS: The cost burden from 
resource utilization increases substantially with metastasis of melanoma. Treatments 
that signiﬁcantly delay disease progression in these patients will reduce this burden.
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HEALTH CARE RESOURCE UTILIZATION (HRU) IN ADVANCED 
OVARIAN CANCER-FINDINGS FROM LINKED SEER-MEDICARE DATA
Parthan A1, Gao SK2, Song R3, Borker R2, Langeberg WJ2, Teitelbaum A3, Oglesby A2
1i3 Innovus, San Francisco, CA, USA, 2Amgen, Inc., Thousand Oaks, CA, USA, 3i3 Innovus, 
Eden Prairie, MN, USA
OBJECTIVES: To estimate the health care costs, treatment patterns, and health care 
resource use in advanced ovarian cancer (aOC) patients receiving ﬁrst line chemo-
therapy. METHODS: Incident aOC patients between 2000–2005 were identiﬁed from 
the linked Surveillance, Epidemiology and End-Results (SEER)/Medicare data ﬁle using 
an ICD-9 code 56.9 with a “distant” tumor in the SEER staging variable. Women ≥65 
years at the time of aOC diagnosis (i.e. index date), with at least three months of data 
preceding the initial diagnosis were included. Subjects were followed from 30 days 
prior to index date until the ﬁrst occurrence of the following: receipt of a 2nd line treat-
ment given after a minimum of 90 days treatment free interval, death or the end of the 
Medicare claims data (i.e., December 2007). Measures of overall HRU included hospi-
talizations, outpatient visits, physician visits, hospice care, home health care, and 
skilled nursing facility utilization. Costs of each HRU event were estimated by summing 
all Medicare payments, primary insurer payments, patient copayments and deductibles 
for services in the claims ﬁles. Average health care costs per event per patient (e.g. 
hospitalization) are calculated as total cost per event divided by number of patients with 
the event. RESULTS: A total of 3895 aOC subjects receiving ﬁrst-line chemotherapy 
were included in the analysis. Mean age was 75 years. Carboplatin+paclitaxel (73%), 
carboplatin alone (8.5%), and carboplatin+docetaxel (7%) were the three most com-
monly used 1st line chemotherapeutic agents. The mean 1st line treatment duration was 
128 days (SD 95.8). The rate of hospitalization was 1.5 per person-year. Mean hospi-
talization cost per patient was $12,997 (SD $10,499). Mean SNF and Hospice Care 
costs per patient were $7,509 (SD $7,171) and $7,025 (SD $11,370) respectively. 
CONCLUSIONS: Carboplatin-paclitxel combination was the most commonly used 
ﬁrst line chemotherapeutic regimen. In aOC patients, hospitalization costs were sub-
stantial in women with aOC receiving 1st line chemotherapy.
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FIRST YEAR INSURER AND PATIENT COSTS ASSOCIATED WITH 
HEPATOCELLULAR CARCINOMA DIAGNOSIS IN THE U.S. MANAGED 
CARE POPULATION
Tsong W, Ray S
Abbott Laboratories, Abbott Park, IL, USA
OBJECTIVES: To evaluate insurer and patient cost increases during the ﬁrst year 
following hepatocellular carcinoma (HCC) diagnosis. METHODS: Subjects in the 
Medstat MarketScan® claims database (July 1, 2005–June 30, 2008) were included 
for analysis if they were age ≥18 years, had ≥1 HCC claim (ICD9 155.0) from July 
1, 2006 to June 30, 2007, no cancer claims in the year prior to the ﬁrst HCC claim 
(index), and a full year of pre-index data. Per patient per month (PPPM) cost estimates 
were compared pre- and post- diagnosis with a sign rank test. RESULTS: The analyti-
cal dataset included 440 patients: mean age 53 years, 61% male, mean follow-up 256 
